Recommendations

Document Overview

Design and created by Guideline Central in participation with the American Society for Transplantation and Cellular Therapy.

Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation

American Society for Transplantation and Cellular Therapy

Publication Date: May 8, 2014

Page Last Updated: May 5, 2026

Recommendation Grading

Document Overview

Document Title: Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation

Authoring Society: American Society for Transplantation and Cellular Therapy

Document Publication Date: May 8, 2014

Page Last Reviewed/Updated: May 5, 2026

Document Type: Guideline

Country of Publication: United States

Full Text Freely Available: Yes

Full Text Guideline: www.bbmt.org/article/S1083-8791(14)00288-2/fulltext

Supplemental Implementation Resources

Quick-Reference Guide

Document Scope, Criteria, and Use Cases

Scope: Assessment and Screening, Management, Treatment

Diseases/Conditions (MeSH)

D019650 - Hematopoietic Stem Cell Mobilization

Keywords: Hematopoietic transplantation, Peripheral blood, Progenitor cell mobilization

Inclusion Criteria: Female, Male, Adolescent, Adult, Child, Older Adult

Health Care Settings: Hospital, Operating and Recovery Room, Outpatient

Intended Users: Clinical Researcher, Nurse, Nurse Practitioner, Physician, Physician Assistant

Recommendation Development Processes & Methodology

Number of Source Documents: 114

Includes peer/external review process?: Yes

Includes public comment process?: No

Methodologist involvement?: Yes

Patient involvement?: No

Includes multi-disciplinary group?: Yes

Includes systematic review?: Yes

Grades quality of strength of evidence?: Yes

Grades quality of strength of recommendation?: Yes

Discloses funding source?: No

Discloses conflicts of interest?: Yes

Includes benefits/harms analysis with recommendations?: No

A	Directly based on meta-analysis of RCTs, Well-designed RCTs or diagnostic studies performed on a population similar to the guideline's target population
B	Directly based on RCTs or diagnostic studies with minor limitations; overwhelmingly consistent evidence from observational studies
C	Directly based on observational studies (case control and cohort design)
D	Directly based on expert opinions, case reports, nonsystematic reviews
LB	Laboratory based
NR	Not Rated

Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation

Recommendations

Allogeneic Donors

What is the best myeloid growth factor and dose schedule for mobilization for adult patients?

Is stem cell mobilization safe and effective for pediatric patients? What is the best myeloid growth factor and dose schedule for pediatric patients?

What are the target CD34+ doses for collection and infusion for adult patients?

What are the target CD34+ cells doses for collection and infusion for pediatric patients?

What type of venous access is recommended?

Autologous Donors: Initial Mobilization Attempt

What is the optimal myeloid growth factor and dose schedule for initial mobilization for adult patients?

For growth factor only stem cell mobilization:

For chemotherapy combined with growth factor for stem cell mobilization:

What type of chemotherapy and dose is recommended for chemomobilization in adult patients?

What is the optimal myeloid growth factor and dose schedule for initial mobilization for pediatric patients?

For growth factor only stem cell mobilization:

For chemotherapy combined with growth factor for stem cell mobilization:

What type of chemotherapy and dose is recommended for chemomobilization in pediatric patients?

What are the target goals for collection from adult and pediatric patients?

When should you begin monitoring peripheral CD34+ counts?

For growth factors alone:

For growth factors and chemotherapy:

For growth factors and plerixafor:

When should you initiate leukapheresis?

For growth factors alone:

For growth factors and plerixafor:

For growth factors and chemotherapy:

Considerations for Special Populations, Comorbidities, and Other Topics

Patients at high risk of stem cell mobilization failure or for remobilization attempt

High-risk patients:

For those who have failed initial mobilization attempt:

Pediatric patients with low weight

Obese patients

Should dosing be according to ideal or actual body weight?

How to address thrombocytopenia?

For allogeneic stem cell donors:

For autologous stem cell transplant:

Is there a threshold for leukocytosis for which growth factors should be held?

Are G-CSF biosimilars recommended for use in PBPC mobilization?

Recommendation Grading

Document Overview

Supplemental Implementation Resources

Document Scope, Criteria, and Use Cases

Recommendation Development Processes & Methodology

What are the target CD34⁺ doses for collection and infusion for adult patients?

What are the target CD34⁺ cells doses for collection and infusion for pediatric patients?

When should you begin monitoring peripheral CD34⁺ counts?